03:09 PM EDT, 05/21/2024 (MT Newswires) -- Majority of patients in the US who started weight-loss drug treatment discontinued the treatment before realizing a "clinically meaningful health benefit," according to study by Blue Cross Blue Shield Association members.

The survey covered the use of the drug from 2014 when it was first approved in the US, until 2023. It showed 58% of patients discontinued the treatment before material effects begin to show.

Nearly 30% of individuals prescribed to weight-loss drugs discontinued their usage within the first month, the research conducted by Blue Health Intelligence found. However, those prescribed to these medicines by endocrinologist or obesity medicine specialist were more likely to stay on the regimen for longer.

The study focused on patients prescribed to Novo Nordisk's ( NVO ) Saxenda and Wegovy.

Price: 134.61, Change: +1.70, Percent Change: +1.28